Abstract
The epitranscriptomics of the SARS-CoV-2 infected cell reveals its response to viral replication. Among various types of RNA nucleotide modifications, the m6A is the most common and is involved in several crucial processes of RNA intracellular location, maturation, half-life and translatability. This epitranscriptome contains a mixture of viral RNAs and cellular transcripts. In a previous study we presented the analysis of the SARS-CoV-2 RNA m6A methylation based on direct RNA sequencing and characterized DRACH motif mutations in different viral lineages. Here we present the analysis of the m6A transcript methylation of Vero cells (derived from African Green Monkeys) and Calu-3 cells (human) upon infection by SARS-CoV-2 using direct RNA sequencing data. Analysis of these data by nonparametric statistics and two computational methods (m6anet and EpiNano) show that m6A levels are higher in RNAs of infected cells. Functional enrichment analysis reveals increased m6A methylation of transcripts involved in translation, peptide and amine metabolism. This analysis allowed the identification of differentially methylated transcripts and m6A unique sites in the infected cell transcripts. Results here presented indicate that the cell response to viral infection not only changes the levels of mRNAs, as previously shown, but also its epitranscriptional pattern. Also, transcriptome-wide analysis shows strong nucleotide biases in DRACH motifs of cellular transcripts, both in Vero and Calu-3 cells, which use the signature GGACU whereas in viral RNAs the signature is GAACU. We hypothesize that the differences of DRACH motif biases, might force the convergent evolution of the viral genome resulting in better adaptation to target sequence preferences of writer, reader and eraser enzymes. To our knowledge, this is the first report on m6A epitranscriptome of the SARS-CoV-2 infected Vero cells by direct RNA sequencing, which is the sensu stricto RNA-seq.
Introduction
The SARS-CoV-2 has a single-stranded positive-sense RNA genome that replicates exclusively in the cytoplasm of the infected cell. In this cycle, viral RNAs are never synthesized from DNA, and therefore, no viral RNAs are ever produced by transcription (). In the infected cell, the virus generates four RNA species: genomic RNA copies generated by replication (positive sense single-strand), subgenomic RNAs (positive-sense) and the corresponding negative-sense intermediates of both genomic and subgenomic RNAs. (). The non-structural proteins are directly translated from the positive single-strand genomic RNA and post-translationally processed. The infected cell contains, therefore, viral RNAs (genomic and subgenomic) and cellular transcripts (tRNAs, rRNAs, mRNAs, lncRNAs, microRNAs, etc…).
Cellular and viral RNAs are subjected to chemical modifications that increase the nucleotide diversity from the four canonical bases to over 150 different bases and nucleotides that add important biological features to RNAs and are necessary for proper biological function. Among these modifications the m6A is the most common (). Both viral and cellular RNAs are substrates for enzymes that add the methyl group (writers), recognize the signals (readers) and remove the methyl groups (erasers). The m6A methylation is associated with the consensus motif “DRACH”, where the third position is the N6-Methyladenosine flanked by D = G or A or U, R = G or A, and H = A or U or C ().
Besides the viral RNA synthesis, the infection by viruses alters the gene expression patterns of host cells (). It is also expected that the viral infection affects the epitranscriptomics landscape of infected cells and the epigenomic pattern of viral RNAs, by modification of RNA nucleotide moieties, such as methylation. Nucleotide residue modifications are essential for proper functionality of viral RNAs and cellular transcripts by regulating RNA stability, cellular localization, translational control, and immune response escape (; ). Until the advent of the Oxford Nanopore technology for direct RNA sequencing (Oxford Nanopore Technologies, Oxford Science Park, Oxford, UK), the sequence of RNAs were obtained by chemical sequencing of very small RNAs (<100 bases) or deduced from cDNA sequencing, improperly called “RNA-seq” (; ). Also, base modifications were identified by harsh chemical treatments, low resolution antibody-based techniques or laborious mutated reverse transcriptase synthesis (). The Oxford Nanopore direct RNA sequencing, the true RNA-seq, is simple, low-cost technique that readily identifies canonical and modified nucleotide residues, as they are in vivo, by use of a properly trained computational neural network. Because the direct RNA sequencing does not employ PCR or any other synthesis, it is free from PCR bias, polymerase errors, phasing and fluorophore crosstalk ().
The Vero cells are largely used for basic and pre-clinical research. In the course of SARS-CoV-2 Pandemic, these cells were vastly used in pre-clinical tests of a wide range of antiviral drug candidates (; ), vaccine candidates (; ), serving as a main screening method for selection of best candidates to progress on clinical trials. Moreover, the current CoronaVac inactivated virus vaccine (Sinovac Biotech) is produced in this type of cell (). Also, the gold-standard method to evaluate titles of neutralizing anti-bodies after COVID-19, or vaccination, use Vero cell as reporter (; ), reinforcing the clinical and pharmacological relevance of these cells. It is expected that the Vero cell epitranscriptome might be different from the human Calu-3 cells but not so significantly, regarding the viral response, because of highly conserved genes and regulatory pathways in primates. In other words, humans and other primates share common traits, which supports the wide use of Vero cells in medical and pharmacological techniques of SARS-CoV-2 culturing and testing.
By using the direct RNA sequencing technique, we identified a major type of base methylation, the N6-Methyladenosine, or m6A, in viral RNAs from Vero infected cells (). The Vero cell line is derived from the African Green Monkey, or vervet, and is widely used for in vitro Coronavirus propagation (; ). Our results are consistent with previous m6A analysis using “non-direct RNA sequencing” or other studies that used direct RNA-seq although detecting other methylation types, such as 5mC (; ; ; ). Here we extended the viral epigenetic analysis to cellular RNAs of the infected Vero cells and compared to human Calu-3 cells.
Material and methods
Samples
Direct RNA sequencing reads from uninfected and infected Vero cells (Clone E6, ATCC® CRL-1586™), and SARS-CoV-2 reads from Vero cell lysates and cell culture supernatants were obtained from (; ; ). Reads from uninfected, and infected Calu-3 cells, and SARS-CoV-2 reads from Calu-3 cell lysates were obtained from (). The first set of samples used here comes from (), and consists of reads from a sequencing experiment conducted on uninfected Vero cells and another sequencing experiment with Vero cells infected with SARS-CoV-2 (Wuhan-Hu-1 isolate GISAID ID: EPI_ISL_413016). The second set comes from (), and consists of reads from an experiment of infection of Vero cells by SARS-CoV-2 (Wuhan-Hu-1 isolate) and another from viral RNA reads from the supernatant of infected cells. The third sample set sequenced in our laboratory (). Sequencing reads are from Vero cells infected by SARS-CoV-2 (Wuhan-Hu-1 isolate) and reads from viral RNAs of cell culture supernatants. Reads from Calu-3 cells infected by SARS-CoV-2 are from SARS-CoV-2/Australia/VIC01/2020, NCBI: MT007544.1. Sequencing data from uninfected Vero cells (“Vero 24h Control” SRA: SRR13089345) from () were also used. The reference sequences used were: The African Green Monkey annotated transcripts (Ensembl release 105 - Dec 2021) (; ) and the Homo sapiens annotated transcripts (Ensembl Release 106 - Apr 2022), and the SARS-CoV-2 reference sequence (NC045512.2) as detailed below.
Contig assembly by mapping to reference sequences
Raw direct RNA sequencing reads from infected and uninfected Vero cells were obtained from https://doi.org/10.17605/OSF.IO/8F6N9 (), and an additional sample of infected Vero cells and from cell culture supernatant from BioProject Accession PRJNA608224 (). Reads from uninfected and infected Calu-3 cells were obtained by direct RNA sequencing (BioProject Accession PRJNA675370, SRA Accession #SRR13089335 for uninfected Calu-3 cells, and #SRR13089334 for infected Calu-3 cells, and #SRR13089345 for uninfected Vero cells) (). Cell Culture, SARS-CoV-2 Infection, RNA Isolation and Direct RNA Sequencing of the present study were performed as described in (). Direct RNA sequencing and base calling were performed with “High Accuracy Mode” using the Guppy program (v-5.0.11) as described in () and as described elsewhere for third party data (; ; ). Reads from SARS-CoV-2 infected Vero cells contained in fastq files were mapped against the Chlorocebus sabaeus, or vervet, annotated transcripts fasta file from the genome assembly GCA000409795.2 March 2014, NCBI Genome ID: 13136, NCBI Assembly ID: 132581 and NCBI BioProject ID: 215854 (from Ensembl release 105, accessed in December 2021) () and the SARS-CoV-2 Wuhan-Hu-1 (NC045512.2) sequence reference using Minimap2 (v-2.21-r1071) (). Bam file reads were sorted and indexed using Samtools (v-1.13) ().
Methylation analysis
The “index” and “eventalign” modules implemented in Nanopolish (v-0.13.2) were used for the resquiggling step. Segmented raw signals generated in the previous step, and contained in the eventalign file, were pre-processed with ‘m6anet-dataprep’ and the predictions of m6A modifications in DRACH motifs were obtained via ‘m6anet-run_inference’, algorithms implemented in m6anet program (v-1.0.0) (). The program EpiNano v.1.2 (; ) was also used for m6A detection, with the Epinano-SVM method (https://github.com/novoalab/EpiNano). The extraction of base-calling error features was performed with the “Epinano_Variants” module, and the m6A predictions were performed on RRACH motifs with the “Epinano_Predict “ script included.
Analysis of DRACH motifs
To perform a detailed inspection on methylated DRACH motifs - checking for sequence information bias – the consensus sequences were obtained from the variation calling step. This procedure was performed with Longshot (v.0.4.1), with default settings for long reads, and establishing a minimum threshold of read depth for 30x coverage to accept the SNV occurrence (). The resulting VCF files obtained in this step were used to generate consensus sequences by the “bcftools consensus” - BCFTools (v.1.15) (). It was then possible to extract all methylated DRACH motifs, flanked by 5 nucleotides at each end to align and stack them using the Tidyverse package (v.1.3.1) (). To minimize the occurrence of m6a sites that may represent false positives in Vero cell samples (presence of methylated m6A sites with a reduced probability of predictions as a function of many transcripts/reads) and that could add noise to the analysis, the inspection of the DRACH motifs was performed using sequences containing m6A sites with ≥ 0.8 probability of modification threshold, and coverage ≥ 30x. To reduce the occurrence of false negatives in SARS-CoV-2 sequences with fewer reads, and a smaller genome size, the methylation probability threshold was set at ≥ 0.5. Because some DRACH motifs (including 5 nucleotides at each end) can be located at the coordinate ends of cellular and viral transcripts, and result in truncated sequences, the removal of these sequences was necessary. The analysis of nucleotide biases in DRACH motifs was performed with ggseqlogo package (v.0.1) ().
Functional enrichment analysis
To map transcripts against known functional information sources and detect statistically significant enriched terms, the gProfiler web server was used (https://biit.cs.ut.ee/gprofiler/gost) (). Overrepresentation was evaluated in terms of Gene Ontology (GO) or through the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (). The main GO categories analyzed were Molecular Function (MF), Biological Process (BP), Cellular Component (CC).
Statistical test for differential methylation
To compare the distributions of methylated sites per transcript in reads from uninfected and infected cells we performed the Wilcoxon-Mann-Whitney (WMW) test as implemented in R version 4.2.1 as a part of R base (; ). This is a nonparametric test to compare differences between two independent groups when they are not normally distributed. Under the null hypothesis H0, the distributions of both groups are identical. The alternative hypothesis H1 is that the distributions are not identical, by detecting a significant difference in the medians. Violin plots were produced with package ggplot2 version 3.3.6. (https://www.rdocumentation.org/packages/ggplot2/versions/3.3.6/topics/ggplot).
Results
Distribution of m6A sites in cellular transcripts
Direct RNA sequencing data from four experiments (13 datasets) were used for assembly. One sample was obtained by our group () and other three samples from (; ; ). The assembly statistics of these samples are shown in Table 1. Samples from Taiaroa et al. were obtained by sequencing on an Oxford Nanopore GridION device (5 flow cells). Reads from Kim et al. were obtained by a 100 ng RNA sample in an Oxford Nanopore MinION device (1 flow cell) with a run for 48 hours whereas the samples from Campos et al. were obtained from a 50 ng RNA sample with a run for 30 hours in an Oxford Nanopore MinION. The differences in number of reads reflect size exclusion in real time basecalling as in , were reads < 500 bases were excluded. Also the RNA preparation used in favored enrichment of viral RNAs as detailed in the Discussion section below.
Table 1
| Total raw reads | Average percent identity | Fraction of bases aligned | Mean read length | Mean read quality | Median percent identity | Median read length | Median read quality | Number of mapped reads | Read length N50 | STDEV read length | Total bases | Total bases aligned | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uninfected Vero () | 1,439,291 | 89.7 | 0.8 | 1,084.3 | 10.6 | 90.8 | 831 | 10.7 | 1,045,491 | 1,371 | 829.1 | 1,133,635,322 | 922,214,398 |
| Infected Vero () | 879,679 | 89.3 | 0.8 | 1,059.6 | 10.4 | 90.4 | 798 | 10.5 | 189,127 | 1,333 | 881.3 | 200,397,442 | 160,417,377 |
| Infected Vero () | 680,347 | 90.1 | 0.8 | 1,067.4 | 10.8 | 91.3 | 803 | 11 | 390,641 | 1,408 | 843 | 416,982,983 | 340,053,176 |
| Infected Vero () | 22,601 | 88.5 | 0.8 | 849 | 11.6 | 89.1 | 732 | 11.7 | 11,727 | 874 | 379.1 | 9,956,327 | 8,336,639 |
| SARS-CoV-2 in lysate () | 879,679 | 90.8 | 1 | 2,585.5 | 10.9 | 91.6 | 1,738 | 11.2 | 645,942 | 3,440 | 2,512.6 | 1,670,076,092 | 1,613,107,683 |
| SARS-CoV-2 in lysate () | 680,347 | 90.8 | 1 | 1,827.1 | 11 | 91.4 | 1,577 | 11.3 | 210,202 | 2,575 | 1,602.7 | 384,054,811 | 373,263,396 |
| SARS-CoV-2 in lysate () | 22,601 | 91.1 | 1 | 1,262.8 | 11.7 | 91.6 | 1,128 | 11.8 | 7,842 | 1,602 | 698.9 | 9,902,573 | 9,636,856 |
| SARS-CoV-2/Supernatant () | 430,923 | 88.8 | 1 | 1,083.5 | 9.9 | 89.6 | 811 | 10.1 | 18,266 | 1,515 | 950.6 | 19,790,887 | 19,270,761 |
| SARS-CoV-2/Supernatant () | 1,488,392 | 89.6 | 1 | 1,376.6 | 10.8 | 90.2 | 1,091 | 11 | 1,721 | 1,905 | 1,103.4 | 2,369,172 | 2,271,417 |
| Uninfected Calu-3 () | 952,606 | 89.5 | 0.9 | 1,111.7 | 10.7 | 90.4 | 864 | 10.8 | 916,464 | 1,434 | 799.9 | 1,018,788,064 | 962,906,633 |
| Infected Calu-3 () | 1,068,683 | 89.6 | 0.9 | 1,106.4 | 10.8 | 90.4 | 865 | 10.9 | 935,132 | 1,428 | 789.9 | 1,034,668,826 | 976,315,097 |
| SARS-CoV-2 Calu-3 () | 1,070,290 | 89.7 | 0.9 | 1,653 | 11 | 90.5 | 1,524 | 11.2 | 98,204 | 2,399 | 1,418 | 162,327,257 | 150,141,191 |
| Uninfected Vero Cell () | 1,452,561 | 88.3 | 0.8 | 1,123.1 | 10.4 | 89.3 | 845 | 10.4 | 1,262,145 | 1,473 | 855.5 | 1,417,475,246 | 1,143,645,900 |
Distribution of read lengths, qualities and mapping in different datasets analyzed in this study.
All data are from Vero cells samples except for the three rows indicating samples from Calu-3 cells.
In the uninfected Vero cell, 4228 m6A sites were found and these sites are distributed in 1871 transcripts and 1717 known genes. Most sites were mapped to transcripts encoded in the VCAN, AMOTL2, and DNAJB1 genes (Supplementary Table S1). The sample infected with SARS-CoV-2 () has 262 m6A sites mapped to 137 transcripts in 112 known genes, in which AMOTL2, TNFAIP3, PLK2 contain the highest number of modifications (Supplementary Table S2). The second infected sample () revealed 1023 sites in 544 transcripts and 488 genes. Genes that contain the largest number of sites are CA12, ARHGAP29, and MYC (Supplementary Table S3). The sequencing of infected cells of our group showed a total of 35 m6A sites, in 24 transcripts that map to 14 known genes (Table 2) which is consistent with observed in other datasets.
Table 2
| Transcript stable ID | Gene coordinate | Gene name | Gene description | Transcript position | Number of reads | Probability of modification |
|---|---|---|---|---|---|---|
| ENSCSAT00000015767.1 | 28:16195607-16199048 | - | – | 758 | 31 | 0.9920354 |
| ENSCSAT00000001773.1 | 11:86509722-86519010 | LUM | lumican | 1106 | 49 | 0.971132 |
| ENSCSAT00000011971.1 | 22:13362375-13364975 | - | – | 554 | 40 | 0.9563033 |
| ENSCSAT00000009109.1 | 19:7000793-7001757 | MIF | macrophage migration inhibitory factor | 435 | 33 | 0.8981868 |
| ENSCSAT00000015767.1 | 28:16195607-16199048 | - | – | 966 | 41 | 0.87318575 |
| ENSCSAT00000008980.1 | 23:54222838-54238006 | SPARC | secreted protein acidic and cysteine rich | 1997 | 37 | 0.8047131 |
| ENSCSAT00000017330.1 | 20:88010616-88015477 | RPS8 | ribosomal protein S8 | 1082 | 37 | 0.8037766 |
| ENSCSAT00000010859.1 | 21:54602398-54632780 | COL1A2 | collagen type I alpha 2 chain | 3830 | 43 | 0.77824545 |
| ENSCSAT00000011971.1 | 22:13362375-13364975 | - | – | 546 | 31 | 0.770081 |
| ENSCSAT00000007846.1 | 15:68596968-68599389 | - | – | 685 | 33 | 0.7656064 |
| ENSCSAT00000005189.1 | 26:48105216-48110896 | ACTC1 | actin alpha cardiac muscle 1 | 1632 | 30 | 0.73731476 |
| ENSCSAT00000000028.1 | MT:10751-12128 | MT-ND4 | mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 | 960 | 31 | 0.733373 |
| ENSCSAT00000007475.1 | 12:60353817-60357759 | - | – | 420 | 46 | 0.7216429 |
| ENSCSAT00000009292.1 | 5:1859454-1862305 | RPS2 | ribosomal protein S2 | 667 | 99 | 0.71115077 |
| ENSCSAT00000011687.1 | 8:68898693-68901812 | RPL7 | ribosomal protein L7 | 998 | 34 | 0.7100177 |
| ENSCSAT00000010859.1 | 21:54602398-54632780 | COL1A2 | collagen type I alpha 2 chain | 4270 | 36 | 0.6952559 |
| ENSCSAT00000013675.1 | 21:14525637-14528513 | MYL7 | myosin light chain 7 | 730 | 43 | 0.6849283 |
| ENSCSAT00000018059.1 | 12:21401910-21402595 | - | – | 675 | 42 | 0.6834394 |
| ENSCSAT00000011706.1 | 26:14002075-14004474 | RPLP1 | ribosomal protein lateral stalk subunit P1 | 198 | 53 | 0.66291857 |
| ENSCSAT00000001773.1 | 11:86509722-86519010 | LUM | lumican | 654 | 45 | 0.6566237 |
| ENSCSAT00000013859.1 | 21:12905280-12914205 | IGFBP3 | insulin like growth factor binding protein 3 | 2371 | 31 | 0.63804483 |
| ENSCSAT00000006068.1 | 23:82798085-82805936 | RACK1 | receptor for activated C kinase 1 | 1250 | 40 | 0.6353171 |
| ENSCSAT00000018668.1 | 18:70826193-70826794 | - | – | 218 | 41 | 0.60119855 |
| ENSCSAT00000000697.1 | 16:66963460-66968731 | - | – | 783 | 34 | 0.59995514 |
| ENSCSAT00000010859.1 | 21:54602398-54632780 | COL1A2 | collagen type I alpha 2 chain | 3800 | 39 | 0.58406496 |
| ENSCSAT00000011706.1 | 26:14002075-14004474 | RPLP1 | ribosomal protein lateral stalk subunit P1 | 513 | 56 | 0.58338195 |
| ENSCSAT00000013859.1 | 21:12905280-12914205 | IGFBP3 | insulin like growth factor binding protein 3 | 2053 | 38 | 0.5830461 |
| ENSCSAT00000018059.1 | 12:21401910-21402595 | - | – | 75 | 49 | 0.57314473 |
| ENSCSAT00000008980.1 | 23:54222838-54238006 | SPARC | secreted protein acidic and cysteine rich | 1943 | 38 | 0.5681411 |
| ENSCSAT00000016933.1 | 6:50663431-50670230 | RPS5 | ribosomal protein S5 | 398 | 45 | 0.55939466 |
| ENSCSAT00000019107.1 | 16:59453767-59454246 | - | – | 8 | 49 | 0.5383941 |
| ENSCSAT00000006068.1 | 23:82798085-82805936 | RACK1 | receptor for activated C kinase 1 | 1030 | 37 | 0.537564 |
| ENSCSAT00000013016.1 | 4:76392625-76396331 | - | – | 275 | 43 | 0.52486014 |
| ENSCSAT00000000555.1 | 6:42666353-42671124 | - | – | 1015 | 90 | 0.5181154 |
| ENSCSAT00000013675.1 | 21:14525637-14528513 | MYL7 | myosin light chain 7 | 519 | 43 | 0.50369656 |
Distribution of m6A sites in the epitranscriptome of the infected Vero cell sample from ().
“-” indicates non-annotated genes in the reference genome.
The comparison of infected Vero cells from the studies by (; ), shows that they share 143 m6A sites. The MYC, PLK2, and PRSS23 genes, for example, share the same 7 methylation sites in each gene (Supplementary Table S4). When we observed samples of infected Vero cells from (), and the sample sequenced by our group, we found 6 m6A sites common to both, distributed over 4 transcripts, one of which mapped to the RACK1 gene (Supplementary Table S5). The samples of infected Vero cells from the study (), and from our sample, share 5 m6A sites, distributed over 4 transcripts (Supplementary Table S6). All infected samples share only 3 m6A sites, located in 2 transcripts from unidentified genes, namely transcript IDs ENSCSAT00000015767.1 (m6A positions 758, coverage 604, and 966, coverage 787) and ENSCSAT00000011971.1 (m6A position 554, coverage 78) (Supplementary Table S7).
The alignment of reads, obtained from the infected Vero cell lysate from the (), to the SARS-CoV-2 reference sequence, revealed 13 m6A sites, 12 of which map to ORF1ab (Supplementary Table S8). The SARS-CoV-2 epigenome from the sample sequenced by (), revealed 7 m6A sites, 4 of which are also located in ORF1ab (Supplementary Table S9). The SARS-CoV-2 epigenome from the cell lysate in our data showed the presence of 5 m6A sites, two of which located in ORF7b, and 2 located in the N gene (Supplementary Table S10). SARS-CoV-2 epigenomes from samples from (; ), share 4 m6A sites, 3 of which are in ORF1ab (Supplementary Table S11). The epigenomes of the three samples obtained from Vero cell lysates share only one m6A site (Supplementary Table S12).
Because the sample set of () contained the largest number of mapped reads (Table 1) this dataset was used to identify differentially methylated transcripts in the Vero cell infected with SARS-CoV-2 (Table 3). This analysis shows 55 differentially methylated sites distributed in 21 known genes. Among identified transcripts, are the Tensin 3 (TNS3), NUAK2, and METTL9 transcripts whose biological functions are relevant. Also, this same dataset allowed the identification of m6A sites unique to transcripts of the infected Vero cells (Table 4). This analysis reveals 47 sites distributed in 37 known genes with attention to the kinase NUAK2, Tensin 3 (TNS3), Ras member B (RHOB) and METTL9.
Table 3
| Transcript stable ID | Gene coordinate | Gene name | Gene description | Position (U) | Reads (U) | Prob. (U) | Position (I) | Reads (I) | Prob. (I) |
|---|---|---|---|---|---|---|---|---|---|
| ENSCSAT00000000076.1 | 11:118913078-118928281 | TMED2 | transmembrane p24 trafficking protein 2 | 884 | 189 | 0.90227556 | 1394 | 33 | 0.80859786 |
| ENSCSAT00000000076.1 | 11:118913078-118928281 | TMED2 | transmembrane p24 trafficking protein 2 | 1703 | 251 | 0.8100335 | – | – | – |
| ENSCSAT00000000890.1 | 6:41640636-41650080 | KDELR1 | KDEL endoplasmic reticulum protein retention receptor 1 | 1107 | 237 | 0.8039204 | 1640 | 38 | 0.8297022 |
| ENSCSAT00000001690.1 | 1:77213836-77324875 | PICALM | phosphatidylinositol binding clathrin assembly protein | 173 | 49 | 0.8412698 | 895 | 33 | 0.8023325 |
| ENSCSAT00000001942.1 | 1:66788240-66799072 | SERPINH1 | serpin family H member 1 | 1561 | 224 | 0.96509045 | 2082 | 31 | 0.94127834 |
| ENSCSAT00000001942.1 | 1:66788240-66799072 | SERPINH1 | serpin family H member 1 | 436 | 87 | 0.8628933 | – | – | – |
| ENSCSAT00000001942.1 | 1:66788240-66799072 | SERPINH1 | serpin family H member 1 | 1233 | 178 | 0.8468479 | – | – | – |
| ENSCSAT00000002495.1 | 7:30805749-30810720 | HNRNPDL | heterogeneous nuclear ribonucleoprotein D like | 2078 | 30 | 0.9407665 | 1576 | 68 | 0.85807246 |
| ENSCSAT00000003445.1 | 9:95672648-95689247 | TRIM8 | tripartite motif containing 8 | 1412 | 46 | 0.9639772 | 2315 | 31 | 0.83026695 |
| ENSCSAT00000003445.1 | 9:95672648-95689247 | TRIM8 | tripartite motif containing 8 | 1568 | 88 | 0.94590265 | – | – | – |
| ENSCSAT00000003445.1 | 9:95672648-95689247 | TRIM8 | tripartite motif containing 8 | 1486 | 69 | 0.90411556 | – | – | – |
| ENSCSAT00000003903.1 | 16:33752556-33799102 | CLTC | clathrin heavy chain | 3347 | 241 | 0.8372275 | 4409 | 40 | 0.8006732 |
| ENSCSAT00000003903.1 | 16:33752556-33799102 | CLTC | clathrin heavy chain | 252 | 139 | 0.8231322 | – | – | – |
| ENSCSAT00000004018.1 | 16:31833160-31900963 | PPM1D | protein phosphatase, Mg2+/Mn2+ dependent 1D | 870 | 76 | 0.9798185 | 2058 | 42 | 0.87876064 |
| ENSCSAT00000004018.1 | 16:31833160-31900963 | PPM1D | protein phosphatase, Mg2+/Mn2+ dependent 1D | – | – | – | 1657 | 37 | 0.8740219 |
| ENSCSAT00000004018.1 | 16:31833160-31900963 | PPM1D | protein phosphatase, Mg2+/Mn2+ dependent 1D | 1396 | 108 | 0.8597186 | – | – | – |
| ENSCSAT00000004018.1 | 16:31833160-31900963 | PPM1D | protein phosphatase, Mg2+/Mn2+ dependent 1D | 2907 | 34 | 0.83353394 | – | – | – |
| ENSCSAT00000004698.1 | 10:117477904-117486774 | NCL | nucleolin | 2309 | 274 | 0.8647666 | 2014 | 33 | 0.87197196 |
| ENSCSAT00000005041.1 | 5:20128176-20175564 | METTL9 | methyltransferase like 9 | 847 | 248 | 0.801356 | 992 | 32 | 0.8637458 |
| ENSCSAT00000005327.1 | 14:96801349-96828716 | PDIA6 | protein disulfide isomerase family A member 6 | 471 | 290 | 0.90395755 | 1509 | 50 | 0.8532138 |
| ENSCSAT00000005327.1 | 14:96801349-96828716 | PDIA6 | protein disulfide isomerase family A member 6 | 1723 | 490 | 0.8176958 | – | – | – |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | 623 | 37 | 0.994408 | 479 | 30 | 0.96617603 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | – | – | – | 916 | 34 | 0.8894909 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | – | – | – | 463 | 30 | 0.8717268 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | – | – | – | 940 | 38 | 0.809437 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | 686 | 65 | 0.970193 | – | – | – |
| ENSCSAT00000008192.1 | 8:122282630-122288384 | MYC | MYC proto-oncogene, bHLH transcription factor | 1336 | 38 | 0.9933568 | 2231 | 42 | 0.8794924 |
| ENSCSAT00000008192.1 | 8:122282630-122288384 | MYC | MYC proto-oncogene, bHLH transcription factor | 2248 | 89 | 0.8645151 | – | – | – |
| ENSCSAT00000009503.1 | 9:32202204-32258154 | ITGB1 | integrin subunit beta 1 | 758 | 338 | 0.80759764 | 1725 | 55 | 0.8165182 |
| ENSCSAT00000012714.1 | 25:24016930-24036641 | NUAK2 | NUAK family kinase 2 | 2434 | 39 | 0.99647045 | 3301 | 30 | 0.95335376 |
| ENSCSAT00000012714.1 | 25:24016930-24036641 | NUAK2 | NUAK family kinase 2 | – | – | – | 3136 | 34 | 0.82845277 |
| ENSCSAT00000012714.1 | 25:24016930-24036641 | NUAK2 | NUAK family kinase 2 | 3165 | 90 | 0.9791137 | – | – | – |
| ENSCSAT00000012714.1 | 25:24016930-24036641 | NUAK2 | NUAK family kinase 2 | 2372 | 37 | 0.93598187 | – | – | – |
| ENSCSAT00000012714.1 | 25:24016930-24036641 | NUAK2 | NUAK family kinase 2 | 3394 | 71 | 0.86949 | – | – | – |
| ENSCSAT00000013859.1 | 21:12905280-12914205 | IGFBP3 | insulin like growth factor binding protein 3 | 1093 | 343 | 0.8282119 | 1378 | 404 | 0.8150883 |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 5866 | 69 | 0.9969953 | 7534 | 31 | 0.884178 |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 5434 | 41 | 0.984392 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 5226 | 39 | 0.98384225 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 5129 | 38 | 0.98288566 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 6065 | 61 | 0.9710264 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 6453 | 81 | 0.9707899 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 6145 | 73 | 0.96241 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 5332 | 43 | 0.91376925 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 5659 | 62 | 0.8688911 | – | – | – |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 6577 | 99 | 0.80982953 | – | – | – |
| ENSCSAT00000017358.1 | 20:90002030-90008033 | SLC2A1 | solute carrier family 2 member 1 | 2060 | 114 | 0.98355216 | 2315 | 32 | 0.93140286 |
| ENSCSAT00000017358.1 | 20:90002030-90008033 | SLC2A1 | solute carrier family 2 member 1 | 2302 | 173 | 0.98312795 | – | – | – |
| ENSCSAT00000017358.1 | 20:90002030-90008033 | SLC2A1 | solute carrier family 2 member 1 | 1977 | 135 | 0.94395334 | – | – | – |
| ENSCSAT00000017358.1 | 20:90002030-90008033 | SLC2A1 | solute carrier family 2 member 1 | 2010 | 156 | 0.89053315 | – | – | – |
| ENSCSAT00000017358.1 | 20:90002030-90008033 | SLC2A1 | solute carrier family 2 member 1 | 2093 | 173 | 0.8239867 | – | – | – |
| ENSCSAT00000017703.1 | 20:116843218-116863010 | EFHD2 | EF-hand domain family member D2 | 232 | 39 | 0.8788946 | 1959 | 40 | 0.8244804 |
| ENSCSAT00000018156.1 | 14:87249005-87249592 | RHOB | ras homolog family member B | 260 | 71 | 0.8870451 | 122 | 31 | 0.8521231 |
| ENSCSAT00000018156.1 | 14:87249005-87249592 | RHOB | ras homolog family member B | 359 | 167 | 0.8001116 | – | – | – |
| ENSCSAT00000018928.1 | 6:11479407-11480450 | JUNB | JunB proto-oncogene, AP-1 transcription factor subunit | 1032 | 89 | 0.9923255 | 99 | 36 | 0.9681243 |
| ENSCSAT00000018928.1 | 6:11479407-11480450 | JUNB | JunB proto-oncogene, AP-1 transcription factor subunit | – | – | – | 893 | 60 | 0.9514262 |
Differentially methylated known genes obtained by comparison of uninfected cell (U) and infected cell (I) datasets from ().
Reads = Coverage and Prob. – Probability of m6A methylation as calculated by m6anet program.
Table 4
| Transcript stable ID | Gene coordinate | Gene name | Gene description | Transcript position | Number of reads | Probability of modification |
|---|---|---|---|---|---|---|
| ENSCSAT00000000076.1 | 11:118913078-118928281 | TMED2 | transmembrane p24 trafficking protein 2 | 1394 | 33 | 0.80859786 |
| ENSCSAT00000000813.1 | 6:42108267-42112471 | PPP1R15A | protein phosphatase 1 regulatory subunit 15A | 1760 | 30 | 0.85488987 |
| ENSCSAT00000000813.1 | 6:42108267-42112471 | PPP1R15A | protein phosphatase 1 regulatory subunit 15A | 2022 | 35 | 0.8545834 |
| ENSCSAT00000000890.1 | 6:41640636-41650080 | KDELR1 | KDEL endoplasmic reticulum protein retention receptor 1 | 1640 | 38 | 0.8297022 |
| ENSCSAT00000001690.1 | 1:77213836-77324875 | PICALM | phosphatidylinositol binding clathrin assembly protein | 895 | 33 | 0.8023325 |
| ENSCSAT00000001942.1 | 1:66788240-66799072 | SERPINH1 | serpin family H member 1 | 2082 | 31 | 0.94127834 |
| ENSCSAT00000002458.1 | 1:56799838-56813650 | EIF3F | eukaryotic translation initiation factor 3 subunit F | 503 | 44 | 0.80193645 |
| ENSCSAT00000002495.1 | 7:30805749-30810720 | HNRNPDL | heterogeneous nuclear ribonucleoprotein D like | 1576 | 68 | 0.85807246 |
| ENSCSAT00000003445.1 | 9:95672648-95689247 | TRIM8 | tripartite motif containing 8 | 2315 | 31 | 0.83026695 |
| ENSCSAT00000003903.1 | 16:33752556-33799102 | CLTC | clathrin heavy chain | 4409 | 40 | 0.8006732 |
| ENSCSAT00000004018.1 | 16:31833160-31900963 | PPM1D | protein phosphatase, Mg2+/Mn2+ dependent 1D | 2058 | 42 | 0.87876064 |
| ENSCSAT00000004018.1 | 16:31833160-31900963 | PPM1D | protein phosphatase, Mg2+/Mn2+ dependent 1D | 1657 | 37 | 0.8740219 |
| ENSCSAT00000004351.1 | 5:26221337-26225083 | TUFM | Tu translation elongation factor, mitochondrial | 1336 | 35 | 0.8196384 |
| ENSCSAT00000004698.1 | 10:117477904-117486774 | NCL | nucleolin | 2014 | 33 | 0.87197196 |
| ENSCSAT00000005041.1 | 5:20128176-20175564 | METTL9 | methyltransferase like 9 | 992 | 32 | 0.8637458 |
| ENSCSAT00000005327.1 | 14:96801349-96828716 | PDIA6 | protein disulfide isomerase family A member 6 | 1509 | 50 | 0.8532138 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | 479 | 30 | 0.96617603 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | 916 | 34 | 0.8894909 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | 463 | 30 | 0.8717268 |
| ENSCSAT00000006347.1 | 17:41712528-41714126 | IER3 | immediate early response 3 | 940 | 38 | 0.809437 |
| ENSCSAT00000006678.1 | 22:52391813-52417575 | RPN1 | ribophorin I | 1615 | 36 | 0.8343291 |
| ENSCSAT00000007637.1 | 23:75149710-75200192 | ATP6V0E1 | ATPase H+ transporting V0 subunit e1 | 845 | 44 | 0.8655202 |
| ENSCSAT00000007678.1 | 23:74929863-74934532 | DUSP1 | dual specificity phosphatase 1 | 1649 | 49 | 0.9319972 |
| ENSCSAT00000007678.1 | 23:74929863-74934532 | DUSP1 | dual specificity phosphatase 1 | 870 | 33 | 0.86039066 |
| ENSCSAT00000007678.1 | 23:74929863-74934532 | DUSP1 | dual specificity phosphatase 1 | 1281 | 41 | 0.80852 |
| ENSCSAT00000008192.1 | 8:122282630-122288384 | MYC | MYC proto-oncogene, bHLH transcription factor | 2231 | 42 | 0.8794924 |
| ENSCSAT00000009011.1 | 24:72156784-72163500 | SERPINA1 | serpin family A member 1 | 1109 | 40 | 0.84530336 |
| ENSCSAT00000009503.1 | 9:32202204-32258154 | ITGB1 | integrin subunit beta 1 | 1725 | 55 | 0.8165182 |
| ENSCSAT00000011100.1 | 6:309506-321785 | BSG | basigin (Ok blood group) | 1931 | 31 | 0.90602887 |
| ENSCSAT00000011100.1 | 6:309506-321785 | BSG | basigin (Ok blood group) | 1863 | 30 | 0.81299096 |
| ENSCSAT00000012419.1 | 4:90497754-90605481 | CAST | calpastatin | 1944 | 60 | 0.8325281 |
| ENSCSAT00000012714.1 | 25:24016930-24036641 | NUAK2 | NUAK family kinase 2 | 3301 | 30 | 0.95335376 |
| ENSCSAT00000012714.1 | 25:24016930-24036641 | NUAK2 | NUAK family kinase 2 | 3136 | 34 | 0.82845277 |
| ENSCSAT00000012734.1 | 14:45086920-45111271 | CCT4 | chaperonin containing TCP1 subunit 4 | 685 | 55 | 0.8591496 |
| ENSCSAT00000013859.1 | 21:12905280-12914205 | IGFBP3 | insulin like growth factor binding protein 3 | 1378 | 404 | 0.8150883 |
| ENSCSAT00000013875.1 | 21:11292788-11554933 | TNS3 | tensin 3 | 7534 | 31 | 0.884178 |
| ENSCSAT00000014245.1 | 4:54629194-54636032 | PLK2 | polo like kinase 2 | 210 | 36 | 0.8035949 |
| ENSCSAT00000015796.1 | 28:15672442-15694148 | KDELR2 | KDEL endoplasmic reticulum protein retention receptor 2 | 790 | 50 | 0.83011115 |
| ENSCSAT00000015906.1 | 28:13491483-13519507 | CYP3A5 | cytochrome P450 family 3 subfamily A member 5 | 2297 | 52 | 0.81895936 |
| ENSCSAT00000016112.1 | 28:12047529-12060202 | SERPINE1 | serpin family E member 1 | 2083 | 139 | 0.8208885 |
| ENSCSAT00000017104.1 | 20:47783935-47785997 | CCN1 | cellular communication network factor 1 | 411 | 104 | 0.8570591 |
| ENSCSAT00000017358.1 | 20:90002030-90008033 | SLC2A1 | solute carrier family 2 member 1 | 2315 | 32 | 0.93140286 |
| ENSCSAT00000017703.1 | 20:116843218-116863010 | EFHD2 | EF-hand domain family member D2 | 1959 | 40 | 0.8244804 |
| ENSCSAT00000018156.1 | 14:87249005-87249592 | RHOB | ras homolog family member B | 122 | 31 | 0.8521231 |
| ENSCSAT00000018928.1 | 6:11479407-11480450 | JUNB | JunB proto-oncogene, AP-1 transcription factor subunit | 99 | 36 | 0.9681243 |
| ENSCSAT00000018928.1 | 6:11479407-11480450 | JUNB | JunB proto-oncogene, AP-1 transcription factor subunit | 893 | 60 | 0.9514262 |
| ENSCSAT00000019531.1 | 14:37013880-37014947 | PCBP1 | poly(rC) binding protein 1 | 866 | 58 | 0.90854704 |
Unique m6A sites in known genes of the infected sample – obtained by comparison of uninfected and infected cells dataset ().
The comparison of Vero cells data with Calu-3 reveals very similar pattern of transcripts and m6A methylation sites. Figure 1 outlines a set of comparisons made between Vero or Calu-3 cells, by m6A site, transcripts and known genes. Regarding the latter cell type, the Supplementary Tables S13, S14 show which sites are present in one sample or another (uninfected and infected cells), which sites are common to both (Supplementary Table S15), data from (), or which sites are unique to each sample (Supplementary Tables S16, S17) (sample from ). Genes SDC1, PMM2, and SERPINA1 have the greatest number of unique m6A sites in the uninfected cell (Supplementary Table S17). In the infected cell, the unique sites are found mainly in the IFIT2, OASL and IFIT3 genes (40, 29 and 27 sites respectively) (Supplementary Tables S16, S17).
Figure 1
Quantitative analysis of differences in m6A methylation between uninfected and infected Vero cells was performed using the Wilcoxon-Mann-Whiteney test with two independent uninfected datasets and two independent infected datasets: (1)
The 4 pairwise comparisons with the WMW test results are shown as violin plots in Figure 2 for m6A sites detected by program m6anet. All comparisons show higher methylation levels in infected cells with p<0.05. Equivalent reults are obtained for the same analysis for m6A sites detected by program EpiNano as shown in Figure 3. These results are summarised in Table 5. As a control for the method, the WMW test was performed for the comparison of the two uninfected datasets,
Figure 2

Violin plots of the distributions of differentially methylated transcripts in Uninfected and Infected Vero cell datasets using program m6anet. The areas indicate the data distribution of each sample and the horizontal bars in the middle of the areas indicate the Medians. The Effect size and p-values are as obtained by the Wilcoxon-Mann-Whitney test as described in Material and Methods. The abscissas idicate the samples and the ordinates indicate the quantity S=log(methylated sites/transcript), which is the logarithm with base 10 of the proportion of methylated sites per transcript, for all transcript types in each dataset.
Figure 3

Violin plots of the distributions of differentially methylated transcripts between Uninfected and Infected Vero cell datasets of using program EpiNano. The areas indicate the data distribution of each sample and the horizontal bars in the middle of the areas indicate the Medians. The Effect size and p-values are as obtained by the Wilcoxon-Mann-Whitney test as described in Material and Methods. The abscissas idicate the samples and the ordinates indicate the quantity S=log(methylated sites/transcript), which is the logarithm with base 10 of the proportion of methylated sites per transcript, for all transcript types in each dataset.
Table 5
| Comparison (WMW) | # Transcripts | Effect Size | Confidence (95%) | p-value |
|---|---|---|---|---|
| m6anet | ||||
| Kim (U) x Kim (I) | 1871 x 137 | 0.259 | 0.145 - 0.371 | 1.04 × 10-5 |
| Kim (U) x Taiaroa (I) | 1871 x 544 | 0.099 | 0.039 - 0.159 | 1.13 × 10-3 |
| Chang (U) x Kim (I) | 2372 x 137 | 0.231 | 0.117 - 0.344 | 7.77 × 10-5 |
| Chang (U) x Taiaroa (I) | 2372 x 544 | 0.072 | 0.013 - 0.131 | 1.58 × 10-2 |
| * Kim (U) x Chang (U) | 1871 x 2372 | 0.026 | -0.011 - 0.065 | 0.168 |
| EpiNano | ||||
| Kim (U) x Kim (I) | 1064 x 119 | 0.353 | 0.240 - 0.465 | 3.433 × 10-9 |
| Kim (U) x Taiaroa (I) | 1064 x 302 | 0.146 | 0.069 - 0.222 | 1.636 × 10-4 |
| Chang (U) x Kim (I) | 1566 x 119 | 0.314 | 0.200 - 0.428 | 1.632 × 10-7 |
| Chang (U) x Taiaroa (I) | 1566 x 302 | 0.107 | 0.032 - 0.182 | 4.927 × 10-3 |
| * Kim (U) x Chang (U) | 1064 x 1566 | 0.037 | -0.008 - 0.084 | 0.111 |
Results of the Wilcoxon-Mann-Whitney test (WMW) for comparison of differentially methylated transcripts between Uninfected (U) and Infected (I) Vero cell datasets using programs m6anet and EpiNano as indicated.
(*) Comparison between two Uninfected Vero cell datasets. Datasets are as indicated in Table 1, being Kim (
The analysis of the epitranscriptome of Vero cells as inferred using the EpiNano program using data from (
The SARS-CoV-2 m6A epigenome
The epigenome of SARS-CoV-2 from infected Vero cell culture supernatants of (
DRACH motif nucleotide biases
Analysis on sequences flanking m6A sites reveal biases in the DRACH motifs (Figure 4). Figures 4A–D shows DRACH motifs obtained from Vero cell epitranscriptomes. DRACH motifs of SARS-CoV-2 epigenomes obtained from the lysate of infected Vero cells are shown in Figures 4E–G and supernatants in Figures 4H, I. DRACH motifs in host cell epitranscriptomes display the signature GGACU, while DRACH in viral epigenomes display the signature GAACU (Figure 4). Data from human Calu-3 reveals the same pattern as observed in Vero cells (Figures 4J–L).
Figure 4

Methylated DRACH motifs reveal different sequence profiles in the cellular epitranscriptome and the viral epigenome. DRACH sequences containing predicted m6a sites (plus 5 nucleotides for each end) were aligned and stacked together to provide an overview of the informational content of methylated regions. Motif profiles in epitranscriptomes were obtained from uninfected Vero cells (A), and from different samples of infected Vero cells (B–D). DRACH profiles in SARS-CoV-2 epigenomes were obtained from different samples of Vero cell lysates (E–G), and from different samples of supernatants (H, I). Motif profiles in epitranscriptomes obtained from uninfected Calu-3 cells (J), infected Calu-3 cells (K). DRACH profiles in SARS-COV-2 epigenome were obtained from infected Calu-3 cells (L). Direct RNA sequencing data were obtained from
Functional enrichment analysis of epitranscriptomes
Data obtained from Vero cell epitranscriptomes were used as inputs for functional enrichment analyses (Figure 5 and Supplementary Figures S2, S3). Among the main biological processes (BP) related to the transcripts listed in Supplementary Table S2 (sample from
Finally, we performed a functional enrichment analysis of Vero cell transcriptome in our sequence data (Tables 1, 2). The main related BPs were “translation” (GO:0006412), “peptide biosynthetic process” (GO:0043043), and “amide biosynthetic process” (GO:0043604) (Figure 5. KEGG main pathways involved were: “Ribosome” (KEGG:03010), and “Coronavirus disease – COVID-19” (KEGG:05171) (Figure 5).
Discussion
In the present study we tested the hypothesis that the infection of Vero cells by SARS-CoV-2 affects the m6A methylation patterns of cellular transcripts. For this, the transcriptome of the infected cell was sequenced using the Nanopore direct RNA sequencing method (Oxford Nanopore Technologies, Oxford Science Park, Oxford, UK). Datasets from four studies were compared. One from our group (
Statistical analysis of data here presented revealed that the m6A methylation of cellular RNAs is significantly higher in infected cells as compared to uninfected cells (Table 5, Figures 2, 3). This finding is supported by two different m6A detection programs (m6anet and EpiNano) (
The quantitave analysis, via WMW test, shows that the global m6A methylation is higher in infected Vero cells as compared to uninfected cells (Figure 2). Also, results obtained using two different m6A detection programs, m6anet and EpiNano, yield equivalent results (Figures 2, 3). As discussed above it still remains to future work to determine if this global higher m6A methylation is inhibiting or enhancing the translatability of cellular mRNAs. The qualitative analysis, as discussed below, suggests that transcripts of genes involved in translation, peptide and amine metabolism are differentially m6A methylated upon SARS-CoV-2 infection.
The analysis here presented allowed the identification of differentially methylated transcripts and m6A unique sites in the infected cell transcripts (Tables 3, 4) and confirms the general m6A pattern observed with miCLIP and RIP-seq techniques (
The transcriptome-wide analysis shows very strong nucleotide biases in DRACH motifs of cellular transcripts, which use the signature GGACU, both in Vero cells and Calu-3 cells (Figures 4A–D, J, K), whereas in viral RNAs the signature is GAACU (Figures 4E–I, L). In Influenza virus it has been shown that the DRACH motif biases are much less significant, and the Influenza virus signature is AAACN with frequencies A=0.50, G-0.25 and U=0.25 in the first position, A=G=0.50 in the second position and A=33.3, C=33.3, U=0.25 and G=0.83 in the fifth position (
It is important to note that the direct RNA sequencing has been validated by orthogonal methods to identify modified bases as revealed by the comparison with liquid chromatography-tandem mass spectrometry and methylated RNA immunoprecipitation sequencing (MeRIP-seq) (
Functional enrichment analysis is a set of statistical methods to extract biological information from omics data in terms of functional categories. These methods are widely used for the analysis of gene and protein lists and regulatory elements (
Figure 5

Functional enrichment analysis of the infected Vero cell m6A epitranscriptome (dataset from
Here, the epitranscriptomics of the Vero cell was studied because of its widespread use for Coronavirus isolation and propagation in vitro. This cell line is derived from the African Green Monkey, or vervet (Chlorocebus sabaeus) and therefore is a model, or an approximation, for the human infection pattern (
Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Brazil) grant 2020/08943-5 to LJ, MB, FA; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil) grant 405691/2018-1 to CB; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil) grant 303912/2017-0 to MB; JC received a postdoctoral fellowship from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Brazil) grant 2021/13111-1.
Acknowledgments
The authors are deeply thankful to Prof. Fulvio A. Scorza, the director of Escola Paulista de Medicina at UNIFESP, for his inspirational leadership and committed support to the Center for Medical Bioinformatics at the Federal University of São Paulo (UNIFESP), Brazil.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The data presented in this study are deposited in the National Center for Biotechnology Information (NCBI) as BioProject ID: PRJNA861323, BioSamples: SAMN29911639 and SAMN29911623.
Author contributions
MB, JC and LJ conceptualized the work. MB, JM and CB contributed with wet lab data and results. MB, JC, GVA and FA performed the computational analysis and validation. MB, JC and FA wrote the manuscript. All authors have read, edited and agreed to the published version of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.906578/full#supplementary-material
References
1
AgostiniM. L.PruijssersA. J.ChappellJ. D.GribbleJ.LuX.AndresE. L.et al. (2019). Small-molecule antiviral β-d-N 4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol.93, e01348–e01319. doi: 10.1128/JVI.01348-19
2
ArltA.SchäferH. (2011). Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. Eur. J. Cell Biol.90, 545–552. doi: 10.1016/j.ejcb.2010.10.002
3
BayoumiM.MunirM. (2021). Evolutionary conservation of the DRACH signatures of potential N6-methyladenosine (m6A) sites among influenza a viruses. Sci. Rep.11, 4548. doi: 10.1038/s41598-021-84007-0
4
BrocardM.RuggieriA.LockerN. (2017). m6A RNA methylation, a new hallmark in virus-host interactions. J. Gen. Virol.98, 2207–2214. doi: 10.1099/jgv.0.000910
5
BuenoS. M.AbarcaK.GonzálezP. A.GálvezN. M. S.SotoJ. A.DuarteL. F.et al. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in a subgroup of healthy adults in Chile. Clin. Infect. Dis., ciab823. doi: 10.1093/cid/ciab823
6
CamposJ. H. C.MaricatoJ. T.BraconiC. T.AntoneliF.JaniniL. M. R.BrionesM. R. S. (2021). Direct RNA sequencing reveals SARS-CoV-2 m6A sites and possible differential DRACH motif methylation among variants. Viruses13, 2108. doi: 10.3390/v13112108
7
ChangJ. J.-Y.RawlinsonD.PittM. E.TaiaroaG.GleesonJ.ZhouC.et al. (2021). Transcriptional and epi-transcriptional dynamics of SARS-CoV-2 during cellular infection. Cell Rep.35(6):109108. doi: 10.1016/j.celrep.2021.109108
8
ChoiJ.IeongK.-W.DemirciH.ChenJ.PetrovA.PrabhakarA.et al. (2016). N6-methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics. Nat. Struct. Mol. Biol.23, 110–115. doi: 10.1038/nsmb.3148
9
DavydovaE.ShimazuT.SchuhmacherM. K.JakobssonM. E.WillemenH. L. D. M.LiuT.et al. (2021). The methyltransferase METTL9 mediates pervasive 1-methylhistidine modification in mammalian proteomes. Nat. Commun.12, 891. doi: 10.1038/s41467-020-20670-7
10
EdgeP.BansalV. (2019). Longshot enables accurate variant calling in diploid genomes from single-molecule long read sequencing. Nat. Commun.10, 4660. doi: 10.1038/s41467-019-12493-y
11
FayM. P.ProschanM. A. (2010). Wilcoxon-Mann-Whitney or t-test? on assumptions for hypothesis tests and multiple interpretations of decision rules. Stat Surveys4, 1–39. doi: 10.1214/09-SS051
12
FolegattiP. M.EwerK. J.AleyP. K.AngusB.BeckerS.Belij-RammerstorferS.et al. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet396, 467–478. doi: 10.1016/S0140-6736(20)31604-4
13
FontanaM. F.BaccarellaA.PancholiN.PufallM. A.HerbertD. R.KimC. C. (2015). JUNB is a key transcriptional modulator of macrophage activation. J. Immunol.194, 177–186. doi: 10.4049/jimmunol.1401595
14
Garcia-MorenoA.López-DomínguezR.Villatoro-GarcíaJ. A.Ramirez-MenaA.Aparicio-PuertaE.HackenbergM.et al. (2022). Functional enrichment analysis of regulatory elements. Biomedicines10, 590. doi: 10.3390/biomedicines10030590
15
GokhaleN. S.McIntyreA. B. R.McFaddenM. J.RoderA. E.KennedyE. M.GandaraJ. A.et al. (2016). N6-methyladenosine in flaviviridae viral RNA genomes regulates infection. Cell Host Microbe20, 654–665. doi: 10.1016/j.chom.2016.09.015
16
HendraC.PratanwanichP. N.WanY. K.GohW. S. S.ThieryA.GökeJ. (2021). Detection of m6A from direct RNA sequencing using a multiple instance learning framework. bioRxiv. doi: 10.1101/2021.09.20.461055. 2021.09.20.461055.
17
JasinskaA. J.SchmittC. A.ServiceS. K.CantorR. M.DewarK.JentschJ. D.et al. (2013). Systems biology of the vervet monkey. ILAR J.54, 122–143. doi: 10.1093/ilar/ilt049
18
KanehisaM.SatoY.FurumichiM.MorishimaK.TanabeM. (2019). New approach for understanding genome variations in KEGG. Nucleic Acids Res.47, D590–D595. doi: 10.1093/nar/gky962
19
KietrysA. M.VelemaW. A.KoolE. T. (2017). Fingerprints of modified RNA bases from deep sequencing profiles. J. Am. Chem. Soc.139, 17074–17081. doi: 10.1021/jacs.7b07914
20
KimD.LeeJ.-Y.YangJ.-S.KimJ. W.KimV. N.ChangH. (2020). The architecture of SARS-CoV-2 transcriptome. Cell181, 914–921.e10. doi: 10.1016/j.cell.2020.04.011
21
LeeA.KhiabanianH.KugelmanJ.ElliottO.NagleE.YuG.-Y.et al. (2014). Transcriptome reconstruction and annotation of cynomolgus and African green monkey. BMC Genomics15, 846. doi: 10.1186/1471-2164-15-846
22
LiH. (2011). A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics27, 2987–2993. doi: 10.1093/bioinformatics/btr509
23
LiH. (2018). Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics34, 3094–3100. doi: 10.1093/bioinformatics/bty191
24
LiH.HandsakerB.WysokerA.FennellT.RuanJ.HomerN.et al. (2009). The sequence Alignment/Map format and SAMtools. Bioinformatics25, 2078–2079. doi: 10.1093/bioinformatics/btp352
25
LiN.HuiH.BrayB.GonzalezG. M.ZellerM.AndersonK. G.et al. (2021). METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection. Cell Rep.35, 109091. doi: 10.1016/j.celrep.2021.109091
26
LiuH.BegikO.LucasM. C.RamirezJ. M.MasonC. E.WienerD.et al. (2019). Accurate detection of m6A RNA modifications in native RNA sequences. Nat. Commun.10, 4079. doi: 10.1038/s41467-019-11713-9
27
LiuH.BegikO.NovoaE. M. (2021a). EpiNano: Detection of m6A RNA modifications using Oxford nanopore direct RNA sequencing. Methods Mol. Biol.2298, 31–52. doi: 10.1007/978-1-0716-1374-0_3
28
LiuJ.XuY.-P.LiK.YeQ.ZhouH.-Y.SunH.et al. (2021b). The m6A methylome of SARS-CoV-2 in host cells. Cell Res.31, 404–414. doi: 10.1038/s41422-020-00465-7
29
LópezM. V.VinzónS. E.CafferataE. G. A.NúñezF. J.SotoA.Sanchez-LamasM.et al. (2021). A single dose of a hybrid hAdV5-based anti-COVID-19 vaccine induces a long-lasting immune response and broad coverage against VOC. Vaccines (Basel)9, 1106. doi: 10.3390/vaccines9101106
30
MannH. B.WhitneyD. R. (1947). On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat18, 50–60. doi: 10.1214/aoms/1177730491
31
MaoY.DongL.LiuX.-M.GuoJ.MaH.ShenB.et al. (2019). m6A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2. Nat. Commun.10, 5332. doi: 10.1038/s41467-019-13317-9
32
MardisE.McCombieW. R. (2017). RNA-Seq: RNA conversion to cDNA and amplification. Cold Spring Harb. Protoc.2017. doi: 10.1101/pdb.prot094672. pdb.prot094672.
33
MercadanteA. A.DimriM.MohiuddinS. S. (2022)“Biochemistry, replication and transcription,”. In: StatPearls (Treasure Island (FL: StatPearls Publishing). Available at: http://www.ncbi.nlm.nih.gov/books/NBK540152/ (Accessed April 20, 2022).
34
NakagawaK.LokugamageK. G.MakinoS. (2016). Viral and cellular mRNA translation in coronavirus-infected cells. Adv. Virus Res.96, 165–192. doi: 10.1016/bs.aivir.2016.08.001
35
PfeifferF.GröberC.BlankM.HändlerK.BeyerM.SchultzeJ. L.et al. (2018). Systematic evaluation of error rates and causes in short samples in next-generation sequencing. Sci. Rep.8, 10950. doi: 10.1038/s41598-018-29325-6
36
QianX.LiG.VassW. C.PapageorgeA.WalkerR. C.AsnaghiL.et al. (2009). The tensin-3 protein, including its SH2 domain, is phosphorylated by src and contributes to tumorigenesis and metastasis. Cancer Cell16, 246–258. doi: 10.1016/j.ccr.2009.07.031
37
RaudvereU.KolbergL.KuzminI.ArakT.AdlerP.PetersonH.et al. (2019). g:Profiler: A web server for functional enrichment analysis and conversions of gene list. Nucleic Acids Res.47, W191–W198. doi: 10.1093/nar/gkz369
38
Rhesus Macaque Genome Sequencing and Analysis ConsortiumGibbsR. A.RogersJ.KatzeM. G.BumgarnerR.WeinstockG. M.et al. (2007). Evolutionary and biomedical insights from the rhesus macaque genome. Science316, 222–234. doi: 10.1126/science.1139247
39
Ricardo-LaxI.LunaJ. M.ThaoT. T. N.Le PenJ.YuY.HoffmannH.-H.et al. (2021). Replication and single-cycle delivery of SARS-CoV-2 replicons. Science374, 1099–1106. doi: 10.1126/science.abj8430
40
SadoffJ.Le GarsM.ShukarevG.HeerweghD.TruyersC.de GrootA. M.et al. (2021). Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine. N Engl. J. Med.384, 1824–1835. doi: 10.1056/NEJMoa2034201
41
SchultzD. C.JohnsonR. M.AyyanathanK.MillerJ.WhigK.KamaliaB.et al. (2022). Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature, 604:134–140. doi: 10.1038/s41586-022-04482-x
42
TaiaroaG.RawlinsonD.FeatherstoneL.PittM.CalyL.DruceJ.et al. (2020). Direct RNA sequencing and early evolution of SARS-CoV-2. bioRxiv. doi: 10.1101/2020.03.05.976167
43
ViehwegerA.KrautwurstS.LamkiewiczK.MadhugiriR.ZiebuhrJ.HölzerM.et al. (2019). Direct RNA nanopore sequencing of full-length coronavirus genomes provides novel insights into structural variants and enables modification analysis. Genome Res.29, 1545–1554. doi: 10.1101/gr.247064.118
44
V’kovskiP.KratzelA.SteinerS.StalderH.ThielV. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol.19, 155–170. doi: 10.1038/s41579-020-00468-6
45
WagihO. (2017). Ggseqlogo: A versatile r package for drawing sequence logos. Bioinformatics33, 3645–3647. doi: 10.1093/bioinformatics/btx469
46
WarrenW. C.JasinskaA. J.García-PérezR.SvardalH.TomlinsonC.RocchiM.et al. (2015). The genome of the vervet (Chlorocebus aethiops sabaeus). Genome Res.25, 1921–1933. doi: 10.1101/gr.192922.115
47
WennerbergK.DerC. J. (2004). Rho-family GTPases: it’s not only rac and rho (and I like it). J. Cell Sci.117, 1301–1312. doi: 10.1242/jcs.01118
48
WheatleyA. K.JunoJ. A.WangJ. J.SelvaK. J.ReynaldiA.TanH.-X.et al. (2021). Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun.12, 1162. doi: 10.1038/s41467-021-21444-5
49
WickhamH.AverickM.BryanJ.ChangW.McGowanL. D.FrançoisR.et al. (2019). Welcome to the tidyverse. J. Open Source Software4, 1686. doi: 10.21105/joss.01686
50
WoolseyC.BorisevichV.PrasadA. N.AgansK. N.DeerD. J.DobiasN. S.et al. (2021). Establishment of an African green monkey model for COVID-19 and protection against reinfection. Nat. Immunol.22, 86–98. doi: 10.1038/s41590-020-00835-8
51
WylerE.MösbauerK.FrankeV.DiagA.GottulaL. T.ArsièR.et al. (2021). Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy. iScience24, 102151. doi: 10.1016/j.isci.2021.102151
52
YuanW.-C.Pepe-MooneyB.GalliG. G.DillM. T.HuangH.-T.HaoM.et al. (2018). NUAK2 is a critical YAP target in liver cancer. Nat. Commun.9, 4834. doi: 10.1038/s41467-018-07394-5
Summary
Keywords
epigenetics, epitranscriptome, RNA methylation, SARS-CoV-2 Genome, m6A, direct RNA sequencing
Citation
Campos JHC, Alves GV, Maricato JT, Braconi CT, Antoneli FM, Janini LMR and Briones MRS (2022) The epitranscriptome of Vero cells infected with SARS-CoV-2 assessed by direct RNA sequencing reveals m6A pattern changes and DRACH motif biases in viral and cellular RNAs. Front. Cell. Infect. Microbiol. 12:906578. doi: 10.3389/fcimb.2022.906578
Received
28 March 2022
Accepted
25 July 2022
Published
16 August 2022
Volume
12 - 2022
Edited by
Magno Junqueira, Federal University of Rio de Janeiro, Brazil
Reviewed by
Sonia Zuñiga, National Center for Biotechnology (CSIC), Spain; Redmond Patrick Smyth, Helmholtz Institute for RNA-based Infection Research (HIRI), Germany
Updates

Check for updates
Copyright
© 2022 Campos, Alves, Maricato, Braconi, Antoneli, Janini and Briones.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marcelo R. S. Briones, marcelo.briones@unifesp.br
This article was submitted to Virus and Host, a section of the journal Frontiers in Cellular and Infection Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.